New Once-Daily drug could simplify Wilson's disease treatment
NCT ID NCT07465718
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial compares a new once-daily formulation of trientine tetrahydrochloride (TETA 4HCl) to the standard drug D-penicillamine for people newly diagnosed with Wilson's disease. About 38 adults and children (ages 8 and up, weighing at least 55 lbs) will be randomly assigned to one of the two treatments for 48 weeks. The study aims to see if the new pill is safe and effective at controlling copper levels in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trientine tetrahydrochloride (TETA 4HCl)
What this could lead to
If it works, this could offer a simpler once-daily treatment option for Wilson's disease, potentially improving adherence and quality of life.
What could go wrong
This is a small Phase 3 trial with only 38 participants, so results may not apply to everyone. The new drug may not be as effective as the standard treatment, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Colorado Anschutz School of Medicine
Denver, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan Medical Centre
Ann Arbor, Michigan, 48109-2029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale University School of Medicine
New Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact